Pagina 1 a partire dal 24 risultati
FIELD OF THE INVENTION
The invention is directed to novel synthetic C-glycolipids, which are useful in treating cancer, infectious diseases and autoimmune diseases. Specifically, the invention is directed to novel synthetic analogs of .alpha.-C-galactosylceramides, which are potent mediators of
FIELD OF THE INVENTION
The invention is directed to novel synthetic C-glycolipids, which are useful in treating cancer, infectious diseases and autoimmune diseases. Specifically, the invention is directed to novel synthetic analogs of .alpha.-C-galactosylceramides, which are potent mediators of
FIELD OF THE lNVENTION
The present invention is concerned with anti-cancer therapies which utilize selective DNA polymerase substrate analogues as the basis for treatment and is directed to specific means for selectively employing the activity of terminal deoxynucleotidyl transferase, the unique DNA
FIELD OF INVENTION
This invention relates to compositions, methods utilizing fructose and other monosaccharides for the diagnosis of cancer.
BACKGROUND
All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically
FIELD OF THE INVENTION
The present invention relates to pharmaceuticals that affect cell adhesion, inhibit cancer cell metastasis, and induce apoptosis both in vitro and in vivo.
Background of the Invention
Cell adhesion is one important property that differentiates multi-cellular organisms from
TECHNICAL FIELD
This invention relates to a novel ameliorating agent for cancer chemotherapy. More particularly, this invention relates to an ameliorating agent for cancer chemotherapy containing as an active ingredient a water-soluble chromanol glycoside.
BACKGROUND ART
Cancers have been a disease
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to foreign patent application 1310/DEL/2006, filed May 30, 2006 in India.
FIELD OF THE INVENTION
The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims, under 35 U.S.C. .sctn. 119, the priority of Korean Patent Application No. 10-2015-0081418, filed on Jun. 9, 2015 in the Korean Intellectual Property Office, the disclosure of which is incorporated herein by reference in its
This invention is concerned with cis-diammineplatinum(II) organophosphate complexes. More particularly, this invention is concerned with cis-diammineplatinum(II) organophosphate complexes, where the organophosphate moiety is either a glycerophosphate or a monosaccharide phosphate. These complexes
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to compositions and methods for inhibiting reverse transcription, and, more particularly, to such compositions and methods for creating a nucleoside analog that disrupts the hybridization step during reverse
BACKGROUND OF THE INVENTION
Reliance on glycolysis has been correlated with disease progression in cancer, and as well as a consistent and significant increase in activity of hexokinase, phosphofructokinase and pyruvate kinase. Hypoxia is also a feature of many solid cancers and has been linked to
1. INTRODUCTION
The present invention relates to methods and compositions comprising at least one endothelin antagonist, preferably in combination with a poly-.beta.-1.fwdarw.4-N-acetylglucosamine (p-GlcNAc) polysaccharide matrix, for use in the treatment of cancer and other proliferative diseases.
Growth factors comprise a family of polypeptides with a manyfold of properties regulating for example cell proliferation and cell metabolism. As being multi-functional molecules, they may stimulate or inhibit cell proliferation as well as affect cell function depending on the type of the target
FIELD OF THE INVENTION
The present invention relates to novel synthetic structural mimics of bacterial Lipid-A and methods of synthesis of such analogs. Bacterial Lipid-A compositions are being widely used as adjuvant to enhance the immune responses to various antigens used in vaccine formulations.
TECHNICAL FIELD
The present invention relates to tetraphenylbacteriochlorin derivatives, particularly, tetraphenylbacteriochlorin derivatives substituted by monosaccharide residues and their salts, a method of producing the same and compositions as photosensitizers containing the same, especially